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Abstract
Technological advances in RNA biology greatly improved transcriptome profiling during the last two decades. Besides the discovery of many
small RNAs (sRNA) that are involved in the physiological and pathophysiological regulation of various cellular circuits, it becomes evident that
the corresponding RNA genes might also serve as potential biomarkers to monitor the progression of disease and treatment. sRNA gene candi-
date npcTB_6715 was previously identified via experimental RNomic (unpublished data), and we report its application as potential biomarker
for the detection of Mycobacterium tuberculosis (MTB) in patient samples. For proof of principle, we developed a multiplex PCR assay and
report its validation with 500 clinical cultures, positive for Mycobacteria. The analysis revealed 98.9% sensitivity, 96.1% specificity, positive and
negative predictive values of 98.6% and 96.8%, respectively. These results underscore the diagnostic value of the sRNA gene as diagnostic
marker for the specific detection of MTB in clinical samples. Its successful application and the general ease of PCR-based detection compared
to standard bacterial culture techniques might be the first step towards ‘point-of-care’ diagnostics of Mycobacteria. To the best of our knowl-
edge, this is the first time for the design of diagnostic applications based on sRNA genes, in Mycobacteria.
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Introduction
npcRNAs (non-protein-coding RNAs) do not encode significant open
reading frames and are not translated into proteins [1]. However,
these RNAs serve important regulatory roles, often in complex with
proteins [2]. npcRNAs are further classified according to RNA
processing patterns [3] or size criteria [4].
sRNAs in bacteria represent small npcRNAs with sizes typically
ranging between 10 and 500 nucleotides (nts) [2, 5]. sRNAs often
encode conserved RNA secondary structure or antisense elements to
allow specific interactions with nucleic acid or protein targets [6],
respectively. Notably, the conservation of either element does not
necessarily entail appreciable primary sequence preservation. In
agreement, deep sequencing uncovered copious instances of spe-
cies-specific non-protein-coding transcripts [5].
Mycobacterium tuberculosis is the causative agent of tuberculosis
(TB). It was responsible for 9.6 million infections in 2014 [7] and an
estimated number of 1.5 million deaths worldwide [4]. The analysis
of global surveillance data revealed that tuberculosis infections are
most widespread in Asia (58%) [7]. Effective control of tuberculosis
outbreaks and appropriate treatment of diseased individuals demands
the timely identification of infected patients. The detection of MTB in
patient samples via PCR is less time consuming, cheaper and pro-
vides most accurate results [8, 9]. In addition, this approach requires
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less sophisticated laboratory equipment than the original, more
demanding cell culture-based methods.
The IS6110 is an insertion element specific for the mycobacterial
complex and is represented by up to 25 copies per genome [10]. So
far, the IS6110 insertion sequence has been extensively exploited as
target for multiplex PCR-based analyses of MTB [11–13]. But, of late
there are reports of extreme instances where genomes of some MTB
strains only contain a single copy of IS6110 [14], while others even
lost the insertion sequence entirely [15, 16]. The recent emergence of
IS6110-negative strains particularly in Southeast Asia [17, 18], war-
rant for alternative targets that can complement the use of IS6110 in
a multiplex-based assay.
Despite of the growing evidence that sRNAs can serve as biologi-
cal markers for many human diseases [19–21], the application of
sRNA genes as targets for diagnosis of infectious agents has so far
not been scrutinized in greater detail [22]. With small size cDNA
libraries and intensive blast analysis, we identified sRNA gene candi-
dates that were specific to MTB complex. Depending on sequence
composition, length and G/C content, these candidates potentially
represent suitable targets for the design of multiplex PCR assays in
combination with IS6110.
To this end, we describe the experimental validation of the
npcTB_6715 sRNA gene as complementing target to IS6110 in a mul-
tiplex PCR assay for the detection of MTB. To reduce false negatives,
amplification controls were designed and routinely included in the
mPCR (multiplex) assay. The PCR test was validated with 500 culture
positive clinical samples, and to rank its diagnostic potential, we com-
pared the results with a standard commercial kit for TB diagnosis
(Genotype Mycobacterium CM Hains line probe assay).
Materials and methods
Bacterial isolates and genomic DNA extraction
All bacterial strains in this study were part of the culture stock collec-
tion of the Department of Microbiology & Parasitology, School of Medi-
cal Sciences and Infectomic Cluster, Advanced Medical and Dental
Institute, Universiti Sains Malaysia. DNA extraction for MTB and non-
tuberculosis mycobacteria (NTM), respectively, was carried out as
described [23]. In brief, the DNA extraction is based on chemical and
enzymatic lysis of the bacterial cells followed by a chloroform-isoamyl
alcohol extraction. Basically, MTB cells were collected into 500 ll Tris-
EDTA buffer, pH 8.0. The cell suspension was then heated for 20 min.
at 80°C. Lysozyme was added (final concentration at 1 mg/ml), followed
by incubation at 37°C for 2 hrs. After the incubation, 10% sodium
dodecyl sulfate (final concentration 1.1%) and proteinase K (final con-
centration at 0.2 mg/ml; Promega Inc. Madison, Wisconsin, USA) were
added. Tubes were gently vortexed gently and incubated at 65°C for
additional 20 min. Next, a mixture of N-acetyl-N,N,N-trimethyl ammo-
nium bromide (CTAB; final concentration of 40 mM) and NaCl (final
concentration of 0.1 M) was added, followed immediately by the addi-
tion of NaCl alone (final concentration 0.6 M). The tubes were again
vortexed before further incubation at 65°C for 10 min. Equal volume
(800 ll) of chloroform-isoamyl alcohol (24:1) was added to each tube,
vortexed and then centrifuged at 12,000 9 g for 5 min. The genomic
DNA in the aqueous phase was precipitated with equal volume of iso-
propanol and washed with 80% ice-cold ethanol. The DNA pellet was
air-dried briefly and resuspended in 20 ll double-distilled water.
For cDNA library construction, MTB H37Rv was grown in Middle-
brook 7H9 broth (Difco, Beckton Dickinson and Company, Sparks, MD
21152, USA) supplemented with 10% Middlebrook ADC enrichment
(Becton, Dickinson and Company, Sparks, MD 21152 USA). Bacterial
cultures were incubated at 37°C in a 250 ml screw cap Erlenmeyer flask
and shaken manually twice per day. Cells were harvested during the
lag, mid-log, stationary and late stationary phases. The cell pellets were
stored at 80°C or directly processed for total RNA extraction.
For all other bacteria (Table S2, excluding MTB and NTM), we fol-
lowed an in-house designed DNA extraction protocol. In brief, 1.5 ml of
bacterial culture was centrifuged at 5000 9 g, the supernatant was dis-
carded and tubes were vortexed to disperse bacterial pellets, the cells
were suspended in 200 ll Solution I (20% sucrose, 50 mM Tris-HCl
[pH 8.0], 1% SDS, 0.2 M NaOH, 25 mM EDTA [pH 8.0], 0.1 M NaCl).
The suspension was subsequently neutralized with 200 ll Solution II
(3 M NaOAc, pH 5.2). After centrifugation at 13,000 9 g, the genomic
DNA was precipitated with 100% ice-cold ethanol, pelleted at
13,000 9 g, washed with 70% ice-cold ethanol, air-dried and re-sus-
pended in 50 ll autoclaved ddH2O. The concentration of the genomic
DNA was measured via the NanoDropTM 2000 system and stored at
20°C until used for PCR.
Total RNA isolation, cDNA library construction
and sequencing
The RNA isolation method is based on single-step guanidine isothio-
cyanate/phenol/chloroform extraction [24]. Cell pellets (100 mg) were
resuspended in 1 ml of TRIzol reagent (Gibco BRL; Life Technologies,
Applied Biosystems Inc., Foster City, California, USA). The suspension
was then transferred to pre-chilled 2 ml screw cap tubes containing
0.1 mm diameter zirconia/silica beads (Biospec Products Bartlesville, OK
74005, USA). Cells were homogenized with the FastPrep-24 (MP
Biomedicals Irvine, California, USA) by subjecting to 3 9 1 min. pulses at
4.5 m/s with 1-minute rests on ice during each interval. The supernatant
was transferred into 1.5-ml microcentrifuge tubes, and total RNA isolation
was conducted according to the manufacturer’s protocol (Gibco BRL, Life
Technologies). To 1 ml of lysate was added: 0.1 ml of 2 M sodium acet-
ate, pH 4.0 and 1 ml water-saturated phenol. The mixture was then mixed
thoroughly by inversion and 0.2 ml chloroform-isoamyl alcohol (49:1)
were added. The resulting biphasic system was vigorously shaken by
hand for 10 sec. The sample was cooled on ice for 15 min. and cen-
trifuged 12,000 9 g for 20 min. at 4°C. The upper aqueous phase was
then carefully transferred to a clean tube, and 1 ml isopropanol was
added for RNA precipitation for at least 1 hr at 20°C. The resulting RNA
pellet was collected by centrifugation for 10 min. at 10,000 9 g at 4°C
and washed with 1 ml of 75% ethanol. Finally, the RNA pellet was air-
dried for 5–10 min. at room temperature and solubilized in 50 ll auto-
claved ddH2O. Total RNA isolated was then treated with DNase (Ambion;
Applied Biosystems, Foster City, California USA).
For analysis of sRNA transcription in MTB, we generated small size
cDNA libraries, which are enriched for candidate sRNAs. Combined total
RNA (200 lg) representing the four different growth stages, lag (5 days),
mid-log (14 days), early stationary (28 days) and late stationary
(50 days), were size fractionated (20–350 nts) on 8% denaturing poly-
acrylamide gels (7 M urea, 19 TBE buffer). Size fractionation of total RNA
starting material via 8% polyacrylamide gel-electrophoresis enabled the
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selection of RNAs with size ranges of 20–350 nts. Passive elution was
conducted in 0.3 M sodium acetate, NaOAc (pH 5.3) overnight at 4°C.
After passive elution, the resulting starting material was 30 C-tailed and
linked to DNA adapters at 50 termini according to Raabe et al., [25]. The
procedure enabled subsequent steps of reverse transcription and single
stranded PCR amplification. The PCR product was then double digested
with SalI (Roche Applied Science, Mannheim, Germany) and NotI (Roche
Applied Science, Mannheim, Germany) restriction endonucleases and
ligated (T4 DNA ligase, Roche Applied Science, Mannheim, Germany) into
the pSPORT1 cloning vector (Invitrogen Life Technologies, Applied Bio-
systems Inc., Foster City, California, USA). Finally, 5400 colonies were
selected at random and sequenced [26]. With the help of Seqman, all
cDNAs were assembled into 3030 contigs, which ultimately represent all
sRNA candidates of our survey. Contigs with sizes below 15 nts were
excluded from downstream analysis.
Bio-computational screens for MTB complex
specific sRNA genes and primer design
50-adapter and C-tail sequences were trimmed from the cDNAs using cus-
tom UNIX scripts. cDNAs that were shorter than 15 nts were excluded from
further analysis. The resulting cDNAs were assembled into contigs using
SeqMan Pro 8.1.5 (LaserGene, DNASTAR, Madison, WI, USA) [27] with
parameters as described by Raabe et al., [25]. The assembled contigs were
manually analysed and mapped against the MTB H37Rv genome (Refseq:
NC_000962) using Basic Local Alignment Search Tool (BlastN) [28]. The
Blast search was conducted with E-values of 105 and a minimal word size
of 11 for the identification of sRNA genes specific for MTB complex. The
NCBI Primer design software (www.ncbi.nlm.nih.gov/tools/primer-blast/inde
x.cgi) was used to design suitable PCR primers for amplification of sRNA
gene, IS6110 and the control plasmid pL250 (Table S1).
mPCR assay
The mPCR assay was conducted with the MyCyclerTM (Bio-Rad Laborato-
ries, Hercules, California, USA) in a total reaction volumes of 20 ll, each
PCR was supplemented with 0.25 lM of forward and reverse primer for
IS6110, npcRNA_6715 and plasmid DNA pL250, 200 lM dNTPs (Fer-
mentas, ThermoFisher Scientific, Waltham, Massachusettes, USA),
1.5 mM MgCl2 (Fermentas ThermoFisher Scientific, Waltham, Massachu-
settes, USA) and 2 U Taq DNA polymerase (Biotools, Madrid Spain) in
19 PCR buffer (10 mM Tris-HCl, [pH 8.3], 50 mM KCl). One ng genomic
DNA served as template for PCR amplification and 10 ng plasmid DNA
pL250 were employed as amplification internal control (AIC) to rule out
false negatives caused by potential PCR inhibitors.
The PCR parameters: initial denaturation at 95°C for 1 min., 30
amplification cycles (i.e. 30 sec. denaturation at 95°C, 30 sec. annealing
at 66°C, 30 sec. extension at 72°C), with final elongation step of 2 min.
at 72°C. The PCR conditions were optimized with varying concentra-
tions of primers, MgCl2, dNTPs and AIC. In addition, annealing tempera-
tures were optimized by gradient PCR. The specificity of the mPCR
assay was determined with 10 NTM species, 7 respiratory tract-asso-
ciated pathogens and 7 normal flora bacteria (i.e. bacteria that would
represent non-diseased physiological conditions) (Table S2). The analyt-
ical sensitivity of the mPCR assay was determined based on the lowest
amount of DNA template per reaction that yields a PCR band of the
expected size in agarose gel electrophoresis.
Gel electrophoresis
All PCR products were analysed by gel electrophoresis. Twenty microli-
tres of each amplified sample was loaded on a 3.5% agarose gel and
electrophoresed in 19 TAE buffer at 60 V for 1 hr. Gels were stained
with ethidium bromide and visualized using a gel-imaging system (Bio-
Rad, USA). PCR product from the samples was randomly chosen and
sequenced [26].
Line probe assay (LPA)
The Line probe assay (GenoType Mycobacterium CM, Hain Lifesciences,
Nehren, Germany) is a molecular test for the identification and differen-
tiation of the MTB complex and common NTM [29]. The assay amplifies
the 23S rRNA gene, followed by reverse hybridization to specific
oligonucleotide probes for different mycobacterial species immobilized
on membrane strip. Hybridization events were detected via colorimetric
changes mediated by the enzymatic reaction of the streptavidin-conju-
gated alkaline phosphatase against the substrate.
The identification of individual mycobacterial species relies on the detec-
tion of specific banding patterns. LPA analysis was performed according to
the manufacturer’s recommendations. In brief, PCR amplifications were
conducted in 50 ll reaction volume, comprising of 35 ll of primer-nucleo-
tide mix, 5 ll of 109 amplification buffer containing 2.5 mM MgCl2 and
1.25 U of hot start Taq polymerase. Five ll genomic DNA (15 ng/ll) and
distilled water were added to adjust the final reaction volumes. The amplifi-
cation products were denatured in a denaturing reagent (provided with the
kit) at room temperature, followed by hybridization at 45°C for 30 min. in a
shaking water bath (Memmert, Germany). After two washing steps, strep-
tavidin conjugated-alkaline phosphatase and the substrate were added for
the colorimetric reaction. To control for cross-contamination, sterile dou-
ble-distilled water in lieu of DNA template was added to the negative control
included for each run. (For details regarding buffer compositions: http://
www.hain-lifescience.de/en/products/microbiology/mycobacteria/genotype-
mycobacterium-cmas.html).
Results and discussion
Analysis of cDNA library
About 19% of all sRNAs within our surveys were derived from pro-
tein-coding mRNAs. Here, the majority of candidate contigs partially
overlapped 50 and 30 termini of annotated CDS regions. Notably, we
also uncovered small antisense transcripts, which reside on the
reverse strand to known CDS sequences in 12% of all sRNA candi-
dates (Fig. 1A). The vast majority of all cDNAs represented tRNA and
ribosomal RNA fragments (60%).
Cis-regulatory elements in bacteria often harbour extended RNA
secondary structures, which convey increased metabolic stability
[30]. The corresponding transcripts are of small size and hence are
frequently detectable in small RNA libraries. Whether these are actual
sRNAs or rather represent simple by-product of the cellular turnover
remains matter of debate [31]. We included even these contigs in our
survey for the identification of genomic regions, which would be
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suitable to design multiplex PCR assays. The resulting contigs were
analysed via blast to identify candidates that are specific for MTB.
Finally out of 3030 cDNA contigs, 80% of the isolated sRNA gene can-
didates are found to be specific to MTB genome (data not shown).
IS6110, en masse with npcTB _6715, as the
diagnostic markers for the mPCR assay
Multiplex PCRs to detect pathogens within patient samples demand
species-specific primer design for identification of the disease-causing
agent and also to discriminate against other yet closely related species
[32, 33]. Here, we evaluate sRNA genes as potential targets for PCR-
based amplification for diagnosis of MTB. The mPCR assay also com-
pensates for drawbacks typically associated with bacterial cell culture
and microscopy for the detection of MTB. The inclusion of additional
targets provides increased selectivity to PCR-based techniques.
Phylogenetic analysis via blast revealed that the npcTB_6715 candi-
date is detectable only within the mycobacterial complex (Supp. Dataset
1-Alignment HitTable). The RNA overlaps partially the 50 leader and CDS
of hypothetical protein LH57_10405 (606 nts) (GenBank: AIR14655.1)
(Fig. S1). The examination of RNA secondary structures via mfold [34]
identified extended RNA stem loop structures. Given its genomic local-
ization, the candidate might be leftover of cis-regulatory circuits to con-
trol AIR14655.1 gene expression. However, its actual molecular
functions are not known. The candidate was selected for PCR assays
based on its sequence features, which allowed simple PCR design.
For long, IS6110 has been target of choice because the multi-copy
sequence is specific for the mycobacterial complex [10]. Recently
however, various reports emphasized the emergence of IS6110-nega-
tive MTB strains [15, 16]. The addition of the sRNA gene as marker
would aid in the detection of IS6110-negative variants. So far, differ-
ent regions of the IS6110 were scrutinized for primer design and
most often they relied on nucleotide positions 762–883 [35]. Here,
we selected PCR primers from position 127–326 nts of the IS6110,
which has not been explored for the design of diagnostic assays.
Optimization of the mPCR assay
Multiplex PCR assays demand extensive optimization to achieve
robust results. The annealing temperature, primer design, MgCl2 and
dNTPs concentrations impact on the efficiency of PCR amplification.
Analysis with gradient PCR revealed that for our assay primer anneal-
ing at 65.2°C is optimal and yields strongest amplification for all three
targets (Fig. S2A–C).
Primer concentration
The parallel application of two primer pairs might cause unexpected
interactions between both PCRs. We titrated primer concentrations in
serial dilutions; all reactions were programmed with 1 ng of M. tuber-
culosis genomic DNA. Finally, 0.1 lM of IS6110 and 0.5 lM of
npcTB_6715 primers yielded balanced amplifications (Fig. S3A, red
box).
The AIC internal control plasmid to identify PCR inhibitors
Depending on specific protocols for genomic DNA extraction
sample contamination by PCR inhibitors must be assumed [36].
We designed the ‘Amplification Internal Control’ (AIC) plasmid as
internal control, which enables the detection of false negative
results. Certainly, AIC concentrations have to be titrated exten-
sively for identification of thresholds that ensure the amplification
of control plasmids but minimize the inhibition of PCRs for other
targets. A wide range of pL250 plasmid DNA concentrations
(1000 ng to 0.1 fg per reaction) was subjected to PCR (Seegene,
USA). The results revealed that concentrations of up to 10 pg
AIC per reaction allow both the detection of effective control and
target gene amplification (Fig. S3B, red box).
The titration of optimal dNTPs and MgCl2 concentrations
To determine the most effective dNTP concentration, serial dNTP
dilutions ranging from 200 to 900 lM were analysed. The stron-
gest amplification was observed with 0.4 mM dNTPs, as evident
by gel electrophoresis (Fig. S4A). Similarly, we analysed the
Fig. 1 (A) Distribution of RNA species
from 4093 clones from cDNA sequences.
cDNA sequences were grouped according
to their annotation and overlap to known
features within the genome. Indicated per-
centage denote the relative number of
cDNAs within our library. (B) Predicted
secondary structure of npcTB_6715.
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optimal MgCl2 concentration with serial dilutions ranging from
1.0 to 2.8 mM. Finally, 1.8 mM MgCl2 proved best and yielded
strongest amplification of both IS6110 and npcTB_6715
(Fig. S4B), respectively.
Analytical specificity of the mPCR
The specificity of the assay was validated with 10 closely related
NTM strains as template. Individual strains were selected accord-
ing to their prevalence within Asia to account for potential cross-
reaction with common targets [37]. In addition, we included
seven pathogens of the lower respiratory tract and seven
microorganisms common to non-diseased individuals. We only
observed successful amplifications for MTB strains (MTB H37Rv
and MTB H37Ra) (Fig. 2A–C). Under these test conditions, the
results revealed 100% specificity. Thus, the assay specifically
detects MTB under test conditions.
Analytical sensitivity of the mPCR
The sensitivity of our mPCR assay was analysed with serial
dilutions of MTB genomic DNA samples (100 ng to 1 pg). The
actual detection threshold was about 100 pg genomic DNA per
20 ll total reaction, which is roughly equivalent to 103 bacteria
(one bacterium contains 10 fg genomic DNA) (Fig. 3, red box)
[38]. Apparently, with this sensitivity, the mPCR assay is about
10 times more sensitive than smear microscopy, which
requires minimally 10,000 AFB/ml sample for the detection of
MTB [39].
Validation of the mPCR with culture positive
samples
For this mPCR assay, samples that contain either the IS6110
(200 nts) or npcTB_6715 (167 nts) amplicon deliver positive sig-
nals. To exclude false negatives, AIC (250 nts) supplement is
mandatory. For validation and to test the mPCR with more diverse
patient material, we utilized genomic DNA derived from 500 culture
positive samples and compared our results with those of the
‘Mycobacterium CM line probe assay’ (LPA). The LPA test is based
on reverse hybridization of PCR products to their complementary
probes and allows the detection of different mycobacteria on (sub)
species level.
With the above collection as template, the LPA analysis identified
371 MTB and 129 NTM samples. Among the latter, 124 samples rep-
resented various NTM isolates (41 Mycobacterium abssessus, 27
Mycobacterium intracelulare, 23 Mycobacterium kansasii, 11
Fig. 2 Specificity of the mPCR assay analysed with 4% agarose gel-electrophoresis. The template DNA was 10 ng of MTB H37Rv genomic DNA per
reaction. Primers for IS6110 and npcTB_6715 were used at 0.1 lM and 0.5 lM, respectively. (A) MTB complex and NTM, Lane 1: 100 bp DNA lad-
der, Lane 2: MTB H37Rv, Lane 3: M. avium, Lane 4: M. abscessus, Lane 5: M. fortuitum, Lane 6: M. fortuitum, Lane 7: M. gordonae, Lane 8:
M. scroferaceum, Lane 9: M. intracellulare. Lane 10: M. kansasii, Lane 11: MTB H37Ra, Lane 12: M. malmoense, Lane 13: Negative control (B)
NTM and lower respiratory pathogens, Lane 1: 100 bp DNA ladder, Lane 2: MTB H37Rv, Lane 3: M. marinum, Lane 4: M. chelonae, Lane 5: Staphy-
lococcus aureus, Lane 6: Streptococcus pneumoniae, Lane 7: Klebsiella pneumoniae, Lane 8: Pseudomonas aeruginosa, Lane 9: Haemophilus
influenza. Lane 10: Haemophilus parainfluenza, Lane 11: Moraxella catarrhalis, Lane 12: Negative control (C) normal flora bacterial strains. Lane 1:
100 bp DNA ladder, Lane 2: MTB H37Rv, Lane 3: Escherichia coli, Lane 4: Bifidobacterium bifidum, Lane 5: Corynebacteria sp., Lane 6: Lactobacil-
lus sp, Lane 7: Neisseria meningitidis, Lane 8: Staphylococcus epidermidis, Lane 9: Coagulase Negative Streptococcus, Lane 10: Negative control.
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Mycobacterium fortuitum, 7 Mycobacterium avium, 4 Mycobacterium
gordonae, 4 Mycobacterium scrofulaceum, 3 Mycobacterium che-
lonae, 1 Mycobacterium xenopi, 1 Mycobacterium ulcerance, 1
Mycobacterium marinum, 1 Mycobacterium malmoense isolates);
and finally 5 samples were classified as non-mycobacterial species.
These results were utilized as reference point to assess the validity of
the mPCR design. Among the 500 samples analysed, 372 (74.4%)
isolates were mPCR positive for MTB. A representative gel picture of
the mPCR result was shown (Fig. S5). Interestingly, with the mPCR
we did not uncover any IS-negative isolate. Finally, the remaining 128
(25.6%) isolates were mPCR negative for MTB, as only the AIC dis-
played substantial PCR signals (which also indicates the absence of
PCR inhibitors) (Table 1 [a]).
Based on the LPA assay, five samples were found to be false posi-
tives and four samples were false negatives. Although in general the
cause of false negative results might be the presence of PCR inhibi-
tors [36], this is highly unlikely due to the successful amplification of
the AIC for all 4 samples. Nevertheless, the cause of false negatives
may be linked to the loss of MTB DNA during the extraction proce-
dure. On the other hand, the false positives might be caused by con-
taminations of the amplicons or the stock culture of the NTM/MTB, or
carry-over during the PCR step.
Our mPCR assay reached sensitivity and specificity levels of 98.9%
and 96.1%, respectively (Table 1 [b]). These values were comparable to
those obtained by other assays based on PCR for the detection of MTB.
Sensitivity and specificity of PCR assays vary widely, ranging from 63
to 100% and from 62 to 100%, respectively [40–45]. The differences in
PCR sensitivities certainly depend on the PCR target [46]. The high sen-
sitivities of our assay substantiated the diagnostic potential of using the
sRNA gene with IS6110 as diagnostic biomarkers for MTB. The PPV
and NPV for this mPCR assay are 98.6% and 96.8% respectively
(Table 1 [b]). These results indicate that the mPCR assay is useful for
the rapid identification of MTB in cultures.
Conclusion
Collectively, our findings demonstrate that the multiplex PCR, amplifying
npcTB_6715 sRNA gene and IS6110, has potential to detect MTB com-
plex especially in culture positive isolates. The detection limit of the
mPCR assay was 100 pg of genomic DNA per reaction. Our novel
sRNA-based mPCR assay may have clinical importance, whereby it can
be use to differentiate between viable and non-viable TB. The sensitivity
and specificity of the mPCR assay were 98.4% and 96.1%, respectively,
which underscore the potential of this assay for specific diagnosis of
MTB. Moreover, the PPV and NPV values of 98.6% and 95.4% were
comparable to that of the LPA. The mPCR assay is also cheaper and
easier to handle because it involves only one amplification cycle com-
pared to the 3 steps of LPA. Thus, the clinical potential of the
npcTB_6715 was corroborated that it can be used alone or in concert
with any target gene for the gene-based detection of MTB.
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individual primer pair with the annealing temperature ranging
from 62C to 70C, run on a 2% agarose gel. (a) IS6110 (b)
npcTB_6715 (c) amplification internal control (AIC). Ladder:
100 bp DNA ladder.
Fig. S3 (A) Optimization of primer concentrations for IS6110
and npcTB_6715 targets in mPCR, run on a 3% agarose gel.
The template DNA was 1 ng of M. tuberculosis H37Rv genomic
DNA per reaction. In each lane, the primer concentrations were
indicated respectively for IS6110 and npcTB_6715 (µM). Lad-
der: 100 bp DNA ladder, (B) Optimization of the amounts of
AIC in the mPCR assay per reaction, run on a 3% agarose gel.
Different amounts of AIC ranging from 1000 ng to 0.1 fg,
10 ng of M. tuberculosis H37Rv genomic DNA, 0.1 µM of
IS6110 primers, and 0.5 µM of npcTB_6715 primers were used
in the reaction. Ladder: 100 bp DNA ladder
Fig. S4 (A) Agarose gel electrophoresis of multiplex PCR using
different concentrations of dNTPs ranging from 200 to 900 µM,
run on a 3% agarose gel. The template DNA was 10 ng of MTB
H37Rv genomic DNA per reaction. Primers for IS6110 and
npcTB_6715 were used at 0.1 µM and 0.5 µM, respectively.
Ladder: 100 bp DNA ladder. (B) Optimization of the amount of
MgCl2 ranging from 1.0 to 2.8 mM, run on a 3% agarose gel.
The template DNA used was 10 ng of MTB H37Rv genomic
DNA per reaction, with 0.1 µM of IS6110 primers and 0.5 µM
of npcTB_6715 primers. Ladder: 100 bp DNA ladder
Fig. S5 Representative gel picture of multiplex PCR products
derived from culture positive samples, analyzed with 4% agar-
ose gel-electrophoresis. M: 100 bp DNA ladder. Lane 1: Nega-
tive control, Lane 2: Positive control, Lane 3-17: 15 culture
positive samples.
Table S1 Primers used in the mPCR
Table S2 Bacterial strains for specificity testing
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